Irritable Bowel Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Tryp Therapeutics, CinRx Pharma, Otsuka Pharmaceutical, RaQualia Pharma, Biomica, Octavian Therapeutics

Irritable Bowel Syndrome Pipeline constitutes 15+ key companies continuously working towards developing 20+ Irritable Bowel Syndrome treatment therapies, analyzes DelveInsight.

Irritable Bowel Syndrome Overview:

Irritable Bowel Syndrome (IBS) is a long-term gastrointestinal disorder marked by abdominal pain, bloating, and irregular bowel habits that may present as diarrhea, constipation, or a combination of both. While its exact cause remains unclear, it is thought to result from multiple factors, including abnormal gut motility, heightened visceral sensitivity, disturbances in gut-brain signaling, and imbalances in the gut microbiota. Triggers differ from person to person but often include certain foods, stress, and hormonal changes. Although there is no cure, management focuses on relieving symptoms through diet modifications, medications, and lifestyle interventions.

The clinical presentation of IBS usually involves recurrent abdominal pain or discomfort, accompanied by bloating and altered bowel patterns. Patients may experience diarrhea, constipation, or alternating episodes of both. Other symptoms can include excessive gas, mucus in stools, and a sensation of incomplete evacuation. Symptom severity varies and may be influenced by diet, stress, or hormonal fluctuations.

Diagnosis is based primarily on symptom criteria, as there is no single definitive test for IBS. Physicians often apply the Rome IV criteria, which require recurrent abdominal pain at least one day per week in the last three months, linked to two or more features: relation of pain to bowel movements, changes in stool frequency, or changes in stool consistency. To exclude other conditions with overlapping symptoms-such as celiac disease or inflammatory bowel disease-doctors may use blood tests, stool analysis, or colonoscopy.

Request for a detailed insights report on Irritable Bowel Syndrome pipeline insights https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Irritable Bowel Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Irritable Bowel Syndrome Therapeutics Market.

Key Takeaways from the Irritable Bowel Syndrome Pipeline Report

DelveInsight's Irritable Bowel Syndrome pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Irritable Bowel Syndrome treatment.
In January 2025, the FDA granted tentative approval to Amneal Pharmaceuticals' generic version of rifaximin 550 mg for treating IBS-D (diarrhea-predominant IBS)-citing ongoing patent litigation with Bausch Health as the reason approval remains tentative.
Key Irritable Bowel Syndrome companies such as Tryp Therapeutics, CinRx Pharma, Otsuka Pharmaceutical, RaQualia Pharma, Biomica, Octavian Therapeutics, and others are evaluating new drugs for Irritable Bowel Syndrome to improve the treatment landscape.
Promising Irritable Bowel Syndrome pipeline therapies in various stages of development include CIN-103, RQ-00310941, OCT-461201, BMC426, and others.

Irritable Bowel Syndrome Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Irritable Bowel Syndrome Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Irritable Bowel Syndrome market.

Download our free sample page report on Irritable Bowel Syndrome pipeline insights https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Irritable Bowel Syndrome Emerging Drugs

CIN-103 - CinRx Pharma

CIN-103 is an innovative formulation of phloroglucinol, a non-opioid small molecule already approved in certain countries for gastrointestinal disorders. It has been designed for long-term use, with CinRx's development team applying both immediate-release and delayed-release technologies to create a proprietary pulsatile delivery system, allowing sustained drug exposure with less frequent dosing. CIN-103 is intended to address multiple mechanisms involved in IBS-D (diarrhea-predominant irritable bowel syndrome), including motility, secretion, pain, spasms, and inflammation. The candidate is currently in Phase II clinical development for IBS.
RQ-00310941 - RaQualia Pharma

RQ-00310941 is a novel 5-HT2B receptor antagonist developed by RaQualia Pharma to target diarrhea-predominant IBS (IBS-D). The 5-HT2B receptor, a subtype of serotonin receptors, plays an important role in regulating gastrointestinal motility. By blocking this receptor, the drug aims to reduce visceral hypersensitivity and normalize abnormal bowel patterns in IBS patients. It is currently in Phase I clinical trials for IBS treatment

Irritable Bowel Syndrome Companies

There are over 15 companies currently working on developing therapies for Irritable Bowel Syndrome (IBS). Among them, CinRx Pharma has a drug candidate that has progressed to the most advanced stage of development-Phase II clinical trials.

Request the Sample PDF to Get Detailed Insights About the Irritable Bowel Syndrome Pipeline Reports Offerings https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Irritable Bowel Syndrome Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Irritable Bowel Syndrome Therapies and Key Companies: Irritable Bowel Syndrome Clinical Trials and advancements https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Irritable Bowel Syndrome Pipeline Therapeutic Assessment
• Irritable Bowel Syndrome Assessment by Product Type
• Irritable Bowel Syndrome By Stage
• Irritable Bowel Syndrome Assessment by Route of Administration
• Irritable Bowel Syndrome Assessment by Molecule Type

Download Irritable Bowel Syndrome Sample report to know in detail about the Irritable Bowel Syndrome treatment market @ Irritable Bowel Syndrome Therapeutic Assessment https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Leber's Hereditary Optic Neuropathy Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.